Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

MLA

Liu, Dan, et al. “Nafamostat Mesylate versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Retrospective Single-Center Study.” European Journal of Medical Research, vol. 29, no. 1, Dec. 2024. EBSCOhost, https://doi.org/10.1186/s40001-024-01660-7.

APA

Liu, D., Zhao, J., Xia, H., Dong, S., Yan, S., Zhuang, Y., Chen, Y., & Peng, H. (2024). Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study. European Journal of Medical Research, 29(1). https://doi.org/10.1186/s40001-024-01660-7

Chicago

Liu, Dan, Jian Zhao, Hui Xia, Shi Dong, Songjuan Yan, Yugang Zhuang, Yuanzhuo Chen, and Hu Peng. 2024. “Nafamostat Mesylate versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Retrospective Single-Center Study.” European Journal of Medical Research 29 (1). doi:10.1186/s40001-024-01660-7.